Claims for Patent: 10,028,965

Summary for Patent: 10,028,965

Title:	Use of sustained release dexamethasone in post-cataract surgery inflammation
Abstract:	The present embodiments provide for a treatment regimen and use of a short-term sustained release liquid formulation of dexamethasone in citrate, wherein a single administration of a minute dosage form into the anterior chamber of the eye provides for anti-inflammatory therapy following cataract surgery.
Inventor(s):	Wong; Vernon G. (Menlo Park, CA), White; William S. (Birmingham, AL), Hu; Mae W. (Los Altos Hills, CA), Huang; Glenn T. (Fremont, CA), Karasina; Faina (Mountain View, CA)
Assignee:	ICON BIOSCIENCE, INC. (Newark, CA)
Application Number:	14/893,381
Patent Claims:	1. A method of treating inflammation of an eye following cataract surgery comprising the steps of: following completion of cataract surgery on the eye, administering by injecting into the eye a single dose of about 4 .mu.L to about 6 .mu.L of a formulation consisting essentially of about 517 .mu.g dexamethasone in triethyl acetyl citrate; wherein said formulation releases said dexamethasone for at least 3 days as measured in saline solution under infinite sink conditions. 2. The method of claim 1, wherein the volume of said dose is about 5 .mu.L. 3. The method of claim 1, wherein said formulation releases said dexamethasone for at least 7 days, as measured in saline solution under infinite sink conditions. 4. The method of claim 1, wherein said formulation releases said dexamethasone for at least 7 days, but no more than 35 days, as measured in saline solution under infinite sink conditions. 5. The method of claim 1, wherein said formulation retains at least 30% of said dexamethasone after 3 days, as measured in saline solution under infinite sink conditions. 6. The method of claim 1, wherein said single dose results in an anterior chamber cell count below 3 within 8 days of administration, when assessed by slit lamp microscopy. 7. The method of claim 1, wherein said single dose results in an anterior chamber cell count below 2 within 30 days of administration when assessed by slit lamp microscopy. 8. The method of claim 1, wherein said dose is injected behind the iris of the eye. 9. The method of claim 1, wherein said dose is injected into the anterior segment of the eye. 10. The method of claim 1, wherein said dose is injected into the anterior chamber of the eye. 11. The method of claim 8, wherein the volume of said dose is about 5 .mu.L.